BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia

Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn, Amy Lehman, James S. Blachly, Arletta Lozanski, Nyla A. Heerema, Weiqiang Zhao, Joshua Coleman, Daniel Jones, Lynne Abruzzo, Amber Gordon, Rose Mantel, Lisa L. Smith, Samantha McWhorter, Melanie Davis, Tzyy Jye Doong, Fan Ny, Margaret Lucas, Weihong ChaseJeffrey A. Jones, Joseph M. Flynn, Kami Maddocks, Kerry Rogers, Samantha Jaglowski, Leslie A. Andritsos, Farrukh T. Awan, Kristie A. Blum, Michael R. Grever, Gerard Lozanski, Amy J. Johnson, John C. Byrd

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Purpose: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods: Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results: With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistancemutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion: Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.

Original languageEnglish (US)
Pages (from-to)1437-1443
Number of pages7
JournalJournal of Clinical Oncology
Volume35
Issue number13
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Recurrence
Mutation
PCI 32765
High-Throughput Nucleotide Sequencing
Natural History
Biomarkers
Agammaglobulinaemia tyrosine kinase
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Woyach, J. A., Ruppert, A. S., Guinn, D., Lehman, A., Blachly, J. S., Lozanski, A., ... Byrd, J. C. (2017). BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. Journal of Clinical Oncology, 35(13), 1437-1443. https://doi.org/10.1200/JCO.2016.70.2282

BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. / Woyach, Jennifer A.; Ruppert, Amy S.; Guinn, Daphne; Lehman, Amy; Blachly, James S.; Lozanski, Arletta; Heerema, Nyla A.; Zhao, Weiqiang; Coleman, Joshua; Jones, Daniel; Abruzzo, Lynne; Gordon, Amber; Mantel, Rose; Smith, Lisa L.; McWhorter, Samantha; Davis, Melanie; Doong, Tzyy Jye; Ny, Fan; Lucas, Margaret; Chase, Weihong; Jones, Jeffrey A.; Flynn, Joseph M.; Maddocks, Kami; Rogers, Kerry; Jaglowski, Samantha; Andritsos, Leslie A.; Awan, Farrukh T.; Blum, Kristie A.; Grever, Michael R.; Lozanski, Gerard; Johnson, Amy J.; Byrd, John C.

In: Journal of Clinical Oncology, Vol. 35, No. 13, 01.05.2017, p. 1437-1443.

Research output: Contribution to journalArticle

Woyach, JA, Ruppert, AS, Guinn, D, Lehman, A, Blachly, JS, Lozanski, A, Heerema, NA, Zhao, W, Coleman, J, Jones, D, Abruzzo, L, Gordon, A, Mantel, R, Smith, LL, McWhorter, S, Davis, M, Doong, TJ, Ny, F, Lucas, M, Chase, W, Jones, JA, Flynn, JM, Maddocks, K, Rogers, K, Jaglowski, S, Andritsos, LA, Awan, FT, Blum, KA, Grever, MR, Lozanski, G, Johnson, AJ & Byrd, JC 2017, 'BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia', Journal of Clinical Oncology, vol. 35, no. 13, pp. 1437-1443. https://doi.org/10.1200/JCO.2016.70.2282
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A et al. BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. Journal of Clinical Oncology. 2017 May 1;35(13):1437-1443. https://doi.org/10.1200/JCO.2016.70.2282
Woyach, Jennifer A. ; Ruppert, Amy S. ; Guinn, Daphne ; Lehman, Amy ; Blachly, James S. ; Lozanski, Arletta ; Heerema, Nyla A. ; Zhao, Weiqiang ; Coleman, Joshua ; Jones, Daniel ; Abruzzo, Lynne ; Gordon, Amber ; Mantel, Rose ; Smith, Lisa L. ; McWhorter, Samantha ; Davis, Melanie ; Doong, Tzyy Jye ; Ny, Fan ; Lucas, Margaret ; Chase, Weihong ; Jones, Jeffrey A. ; Flynn, Joseph M. ; Maddocks, Kami ; Rogers, Kerry ; Jaglowski, Samantha ; Andritsos, Leslie A. ; Awan, Farrukh T. ; Blum, Kristie A. ; Grever, Michael R. ; Lozanski, Gerard ; Johnson, Amy J. ; Byrd, John C. / BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 13. pp. 1437-1443.
@article{03473cb91093493dad00c4c96f92e544,
title = "BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia",
abstract = "Purpose: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods: Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results: With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19{\%} (95{\%} CI, 14{\%} to 24{\%}). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85{\%} (95{\%} CI, 71{\%} to 94{\%}), and these mutations were detected an estimated median of 9.3 months (95{\%} CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistancemutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion: Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.",
author = "Woyach, {Jennifer A.} and Ruppert, {Amy S.} and Daphne Guinn and Amy Lehman and Blachly, {James S.} and Arletta Lozanski and Heerema, {Nyla A.} and Weiqiang Zhao and Joshua Coleman and Daniel Jones and Lynne Abruzzo and Amber Gordon and Rose Mantel and Smith, {Lisa L.} and Samantha McWhorter and Melanie Davis and Doong, {Tzyy Jye} and Fan Ny and Margaret Lucas and Weihong Chase and Jones, {Jeffrey A.} and Flynn, {Joseph M.} and Kami Maddocks and Kerry Rogers and Samantha Jaglowski and Andritsos, {Leslie A.} and Awan, {Farrukh T.} and Blum, {Kristie A.} and Grever, {Michael R.} and Gerard Lozanski and Johnson, {Amy J.} and Byrd, {John C.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1200/JCO.2016.70.2282",
language = "English (US)",
volume = "35",
pages = "1437--1443",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "13",

}

TY - JOUR

T1 - BTKC481S-Mediated resistance to ibrutinib in chronic lymphocytic leukemia

AU - Woyach, Jennifer A.

AU - Ruppert, Amy S.

AU - Guinn, Daphne

AU - Lehman, Amy

AU - Blachly, James S.

AU - Lozanski, Arletta

AU - Heerema, Nyla A.

AU - Zhao, Weiqiang

AU - Coleman, Joshua

AU - Jones, Daniel

AU - Abruzzo, Lynne

AU - Gordon, Amber

AU - Mantel, Rose

AU - Smith, Lisa L.

AU - McWhorter, Samantha

AU - Davis, Melanie

AU - Doong, Tzyy Jye

AU - Ny, Fan

AU - Lucas, Margaret

AU - Chase, Weihong

AU - Jones, Jeffrey A.

AU - Flynn, Joseph M.

AU - Maddocks, Kami

AU - Rogers, Kerry

AU - Jaglowski, Samantha

AU - Andritsos, Leslie A.

AU - Awan, Farrukh T.

AU - Blum, Kristie A.

AU - Grever, Michael R.

AU - Lozanski, Gerard

AU - Johnson, Amy J.

AU - Byrd, John C.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Purpose: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods: Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results: With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistancemutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion: Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.

AB - Purpose: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and natural history of these mutations are limited. Patients and Methods: Patients accrued to four sequential studies of ibrutinib were included in these analyses. Deep sequencing for BTK and PLCG2 was performed retrospectively on patients who experienced relapse and prospectively on a screening population. Results: With a median follow-up time of 3.4 years, the estimated cumulative incidence of progression at 4 years is 19% (95% CI, 14% to 24%). Baseline karyotypic complexity, presence of del(17)(p13.1), and age less than 65 years were risk factors for progression. Among patients who experienced relapse, acquired mutations of BTK or PLCG2 were found in 85% (95% CI, 71% to 94%), and these mutations were detected an estimated median of 9.3 months (95% CI, 7.6 to 11.7 months) before relapse. Of a group of 112 patients examined prospectively, eight patients have experienced relapse, and all of these patients had acquired resistancemutations before relapse. A resistance mutation was detected in an additional eight patients who have not yet met criteria for clinical relapse. Conclusion: Relapse of chronic lymphocytic leukemia after ibrutinib is an issue of increasing clinical significance. We show that mutations in BTK and PLCG2 appear early and have the potential to be used as a biomarker for future relapse, suggesting an opportunity for intervention.

UR - http://www.scopus.com/inward/record.url?scp=85018308247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018308247&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.70.2282

DO - 10.1200/JCO.2016.70.2282

M3 - Article

C2 - 28418267

AN - SCOPUS:85018308247

VL - 35

SP - 1437

EP - 1443

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 13

ER -